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Abstracts / Biol Blood Marrow Transplant 19 (2013) S167eS177 S169Conclusions: Both gE/AS01B and gE/AS01E formulations and
both schedules were immunogenic and well tolerated in
autologous HCT recipients.Table 1
Etanercept arm Placebo arm p
Day 28 Response 62.5% (95%CI:
35.4-84.8)
66.7% (95%CI: 41.0-86.7) .80
Day 56 Response 56.3% (95%CI:
29.9-80.3)
50.0% (95%CI: 26.0-74.0) .72
6 month OS 50.0% (95%CI:
24.5-71.0)
33.3% (95%CI: 13.6-54.5)
Median survival 171 days (95%CI:
11-362)
64 days (95%CI: 26-209)
Log-rank (OS) .51108
Randomized, Double Blind, Placebo-Controlled Trial of
a TNF Inhibitor (ETANERCEPT) for the Treatment of
Idiopathic Pneumonia Syndrome (IPS) After Allogeneic
Stem Cell Transplant (SCT). A Blood and Marrow
Transplant Clinical Trials Network (BMT CTN) Study
Gregory Yanik 1, Vincent T. Ho 2, Mary Horowitz 3,
Daniel J. Weisdorf 4, Brent R. Logan 5, Juan Wu6,
Robert J. Soiffer 7, John R. Wingard 8, John E. Levine 9,
James L.M. Ferrara 9, Sergio A. Giralt 10, Eric White 11,
Shelly L. Carter 6, Nancy DiFronzo 12, Kenneth R. Cooke 13.
1 Blood and Marrow Transplant Program, University of
Michigan, Ann Arbor, MI; 2 Department of Pediatric Oncology
and Stem Cell Transplant, Dana-Farber Cancer Institute,
Boston, MA; 3Medical College of Wisconsin; 4Masonic Cancer
Center, University of Minnesota, Minneapolis, MN; 5Division of
Biostatistics, Medical College of Wisconsin, Milwaukee, WI;
6 The EMMES Corporation, Rockville, MD; 7Harvard Medical
School, Dana-Farber Cancer Institute, Boston, MA; 8 College of
Medicine, Division of Hematology/Oncology, University of
Florida, Gainesville, FL; 9 University of Michigan, Ann Arbor, MI;
10 Department of Medicine, Adult Bone Marrow Transplant
Service, Memorial Sloan-Kettering Cancer Center, New York,
NY; 11 Pulmonary and Critical Care, University of Michigan, Ann
Arbor, MI; 12 Division of Blood Diseases and Resources, NIH/
NHLBI, Bethesda, MD; 13 Pediatric Hematology/Oncology,
University Hospitals Case Western Reserve, Cleveland, OH
IPS is a frequently fatal form of non-infectious pneumonia
occurring early after allogeneic SCT. We conducted a phase III
trial to investigate if a soluble TNF binding protein, etanercept
(Enbrel Amgen), when givenwith corticosteroids, improved
management of IPS. The study was supported by the NHLBI
andNCI,with etanercept supplied byAmgen. Eligible patients
were 18 yrs, within 180 days post allo-SCT, with diffuse
pulmonary inﬁltrates, and absence of active infection, sepsis
syndrome, or cardiogenic shock. A negative BALwas required
at study entry. Patients were randomized to receive eta-
nercept (0.4 mg/kg/dose 2x/week x 4 weeks) or placebo, in
addition to corticosteroids (2.0mg/kg/day,with taperallowed
after 7 days). Response was deﬁned as survival with discon-
tinuation of supplemental oxygen for>72 hours by day 28 of
study. The trial was initially designed to enroll 120 patients,
with sufﬁcient power to identify a 25% response difference
(30% to 55%) between study arms. Due to suboptimal accrual,
inclusion criteria were modiﬁed and expected enrollment
decreased to 60 patients, 30 per arm. The trial did not meet
accrual goals and was stopped after enrolling 34 patients.
Results: Between 2007 and 2011, 34 patients (median age
46.6y, range 22-70 y) were randomized to receive etanercept
(n¼16) or placebo (n¼18). Study arms were balanced for
patient demographics, except for a higher incidence of AML in
the placebo arm (50% vs 6%, P ¼ .02). 50% of etanercept and
55% of placebo treated patients received all intended study
doses, whereas 38% of etanercept and 6% of placebo treated
patients received 25% of intended dosing (primarily inves-
tigator discretion). Response at day 28 and day 56, and overall
survival were comparable between groups (Table 1). There
were no differences in time to discontinuation of supple-
mental oxygen, incidence of grades 3-5 adverse events,
infections, cumulative incidence of relapse, or grades 2-4or 3-
4 acute GVHD. Patients receiving 40% FiO2 at study entry
had response rates of 91% (placebo) and 73% (etanercept)respectively. By comparison, responses in patients receiving
>40% FiO2 at entry were 17% (1 of 6) on the placebo arm and
50% (2 of 4) on the etanercept arm.
Conclusion: No improvement in response or survival was
noted when etanercept was added to corticosteroids for the
treatment of IPS, though the small sample size signiﬁcantly
limits the statistical power of this study. Compared to
historical reports, the response to corticosteroids alone was
higher than anticipated supporting the importance of
studying controls when evaluating a new therapy.TRANSPLANT DATA MANAGEMENT ORAL109
A Culture of Continuous Quality Improvement Improves
Registry Data
Nicolette Maria Minas, Kathleen Ruehle.. University of
Maryland Greenebaum Cancer Center, Baltimore, MD
Background: To ensure the highest degree of accuracy of
CIBMTR (Center for International Blood and Marrow Trans-
plant Research) data, the University of Maryland Blood and
Marrow Transplant team established a culture of continuous
quality improvement. In early 2012, Minas and Ruehle re-
ported the signiﬁcance of auditing 10 commonly used data
collection points. Since that time, their program set out to
identify additional data points of signiﬁcance.
Methods: The Blood and Marrow Transplant Program
Manager and Data Managers continued to evaluate the
quality of their data by selecting 19 additional data points for
audit to assess the signiﬁcance of adding these additional
data points to the 10 commonly used ones. The CIBMTR
forms of four subjects per month (40%) were randomly
selected for audit from August 2011 to August 2012, for
a total of 48 charts.
Results: Our results demonstrated that adding the extra data
points covers 90% of the data reported while the commonly
used data points cover only 50% of the data reported; thereby
demonstrating a more comprehensive review of the infor-
mation reported. Implementing the regular internal audit
using the 10 commonly used data points demonstrated
better percentage (range 89% to 100%) of data accuracy from
that previously reported before implementing the regular
internal audit. When the 19 additional data points were
reviewed as a whole, there was a 96% accuracy rate.
Corrective action was taken by reviewing all CIBMTR forms
with less than 100% accuracy rate and correcting the data in
the electronic database. Education is given on the individual
level and for the group as trends become prevalent.
Conclusion: Implementing internal audits on a regular basis
using the commonly used data points and the additional 19
data points have improved the accuracy of the data from
what has been previously reported. By maintaining
